Multiple myeloma (MM) is a neoplasm of bone marrow (BM) resident plasma cells (PC) that comprises 20% of all hematologic malignancies, and despite new chemotherapeutic agents remains incurable. Myeloma cells are critically dependent on interactions with BM stromal niches for their survival, just like their normal counterparts the BM-resident long-lived PC (LLPC). It is also becoming evident that these interactions play a major role in MM resistance to chemotherapy, the primary cause of treatment failure in this cancer. Despite their central importance however, the specific molecular and cellular components involved in these interactions remain poorly characterized. Although it is primarily characterized as the prototype T cell costimulatory receptor involved in T cell activatio and survival, CD28 is also expressed on normal and malignant PC - and in myeloma its overexpression correlates significantly with poor prognosis, disease progression and shorter survival. Over the last funding cycle, we have shown in patient gene expression profiles that CD28 overexpression is associated with disease progression and poor prognosis patient subgroups, and that activation of CD28 on MM cells protects against chemotherapy-induced death. We have now found that blocking CD28 activation leads to MM cell death in vitro and in vivo, and sensitizes the myeloma to chemotherapy. In addition, we have made the novel observation that PC-intrinsic CD28 function also plays an essential role in sustaining the survival of normal BM LLPC. Thus it appears that CD28 regulates fundamental aspects of normal PC biology that are conserved in myeloma biology due to their essential role in survival. We have subsequently determined that the Vav pathway downstream of CD28 activation transduces CD28's pro-survival signal in BM LLPC. This pathway upregulates expression of the transcriptional regulator BLIMP-1, the "master regulator" of normal PC identity - but whose role in MM biology has been largely unexplored. We now hypothesize that the CD28?Vav pathway regulates a central transcriptional nexus that is required to maintain PC identity, and that this identity is necessary for MM survival and resistance to chemotherapy. The overall goal of this proposal is to define the signaling pathways and molecular targets downstream of CD28 activation that support myeloma cell survival. This understanding is likely to lead to the identification of new therapeutic targets and development of novel treatment strategies for MM, especially chemotherapy resistant disease.
The Specific Aims are: 1). Define the signaling pathways downstream of CD28 activation that intrinsically regulate myeloma cell survival, 2). Define the molecular targets of CD28?Vav signaling that regulate myeloma cell survival, and 3). Determine the anti-myeloma efficacy of blocking CD28 activation in vivo.

Public Health Relevance

Multiple myeloma (MM) is a neoplasm of bone marrow (BM) resident plasma cells that remains incurable. Myeloma cells are critically dependent on BM stromal niches for their survival, and we have found that CD28-CD80/CD86 is a central molecular bridge between MM cells and supportive BM stromal cells - directly transducing a prosurvival signal to the myeloma cell and inducing a stromally generated pro-survival/immunosuppressive milieu. The work proposed will define the molecular components involved and will point to novel therapeutic strategies for targeting these crucial interactions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA121044-07
Application #
8692668
Study Section
Cancer Immunopathology and Immunotherapy Study Section (CII)
Program Officer
Howcroft, Thomas K
Project Start
2006-04-01
Project End
2018-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
7
Fiscal Year
2014
Total Cost
$300,263
Indirect Cost
$108,144
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Koorella, Chandana; Nair, Jayakumar R; Murray, Megan E et al. (2014) Novel regulation of CD80/CD86-induced phosphatidylinositol 3-kinase signaling by NOTCH1 protein in interleukin-6 and indoleamine 2,3-dioxygenase production by dendritic cells. J Biol Chem 289:7747-62
Murray, Megan E; Gavile, Catherine M; Nair, Jayakumar R et al. (2014) CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma. Blood 123:3770-9
Farren, Matthew R; Carlson, Louise M; Netherby, Colleen S et al. (2014) Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKC?II abundance. Sci Signal 7:ra16
Chitta, Kasyapa S; Paulus, Aneel; Ailawadhi, Sikander et al. (2013) Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma 54:387-96
Mannava, Sudha; Zhuang, DaZhong; Nair, Jayakumar R et al. (2012) KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood 119:1450-8
Sher, Taimur; Ailawadhi, Sikander; Miller, Kena C et al. (2011) A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol 154:104-10
Paulus, Aneel; Swaika, Abhisek; Miller, Kena C et al. (2011) Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. J Clin Oncol 29:e47-9
Rozanski, Cheryl H; Arens, Ramon; Carlson, Louise M et al. (2011) Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J Exp Med 208:1435-46
Morales, Alejo A; Kurtoglu, Metin; Matulis, Shannon M et al. (2011) Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 118:1329-39
Nair, Jayakumar R; Carlson, Louise M; Koorella, Chandana et al. (2011) CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 187:1243-53